PharmChem, Inc. Announces Tender Offer
PharmChem, Inc. (OTC: PCHM) has announced a modified Dutch auction tender offer to repurchase up to $5 million of its common stock at prices between $3.25 and $3.75 per share. Shareholders can tender shares within this price range before the offer expires on May 31, 2022. The board believes this method provides an efficient opportunity for shareholders to sell their shares. However, the offer is subject to certain conditions and does not require a minimum number of shares to be tendered.
- Approval of a $5 million stock repurchase, indicating confidence in the company's value.
- The modified Dutch auction format allows flexibility and potentially enhances shareholder value.
- None.
Under the Tender Offer, holders of PharmChem common stock may tender all or a portion of their common shares within the
PharmChem reserves the right, subject to applicable law, to extend, withdraw or terminate the Tender Offer, increase or decrease the Aggregate Maximum Tender Amount or otherwise amend the terms of the Tender Offer. The tender offer will expire at
The Tender Offer will not be conditioned upon any minimum number of shares being tendered, but will be subject to a financing condition, which is described in the Tender Offer materials, as well as certain other customary conditions. PharmChem’s board of directors believes that a modified Dutch auction tender offer is an efficient mechanism that will provide all shareholders with the opportunity to tender all or a portion of their shares. In the future, the board may consider additional tender offer(s) or other measures to enhance shareholder value based on a variety of factors, including the market price of PharmChem’s common stock.
PharmChem’s board of directors has approved the offer. However, neither PharmChem nor the board of directors makes any recommendation as to whether a shareholder should tender or refrain from tendering his or her shares, and neither PharmChem nor the board of directors has authorized any person to make any such recommendation. Shareholders are urged to evaluate carefully all information contained in the Tender Offer materials, consult their own investment and tax advisors, and make their own decision whether to tender shares and, if so, how many shares to tender.
This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any shares of PharmChem common stock. The solicitation and offer to buy shares of PharmChem common stock will only be made pursuant to the offer to purchase and related materials that PharmChem will send to its shareholders. Shareholders should read those materials carefully because they will contain important information, including the various terms and conditions of the tender offer.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005895/en/
InvestorCom
Source:
FAQ
What is the purpose of PharmChem's stock repurchase plan?
What is the price range for PharmChem's tender offer?
When does PharmChem's tender offer expire?
Is PharmChem's tender offer subject to any conditions?